A phase IIb trial of MIN 117 in patients with major depressive disorder in USA

Trial Profile

A phase IIb trial of MIN 117 in patients with major depressive disorder in USA

Planning
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs MIN 117 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Minerva Neurosciences
  • Most Recent Events

    • 06 Nov 2017 According to a Minerva Neurosciences media release, the company plans to initiate patient recruitment in this trial in early 2018.
    • 06 Oct 2016 New trial record
    • 26 Sep 2016 According to a Minerva Neurosciences media release, the US FDA has accepted an Investigational New Drug (IND) application to begin testing of MIN-117 in the United States and this trial is expected to begin in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top